Amarantus Bioscience (PK) Stock Price

0.00255 (25.89%)


52 Week Range


Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Amarantus Bioscience Holdings Inc (PK) AMBS OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00255 25.89% 0.0124 16:00:06
Open Price Low Price High Price Close Price Prev Close
0.01 0.01 0.0124 0.0124 0.00985
Bid Price Ask Price Spread News
0.0099 0.0124 0.0025 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11 138,431 $ 0.010647 $ 1,474 - 0.0045 - 0.018
Last Trade Time Type Quantity Stock Price Currency
15:11:35 8,000 $ 0.0124 USD

Amarantus Bioscience (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.57M 368.41M 125.09M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
22.00k $ - 0.00% - -

more financials information »

Amarantus Bioscience (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMBS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.01180.01330.00940.0106426393,6250.00065.08%
1 Month0.01110.0150.00910.0113878482,0670.001311.71%
3 Months0.00860.01750.0080.0123681675,6060.003844.19%
6 Months0.00650.01750.00450.0090508809,0630.005990.77%
1 Year0.0090.0180.00450.0090995879,2930.003437.78%
3 Years0.04080.078910.00450.0179172696,260-0.0284-69.61%
5 Years0.0720.20850.00450.0299606592,776-0.0596-82.78%

Amarantus Bioscience (PK) Description

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer's aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS also owns approximately 109 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.

Your Recent History
Amarantus ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.